Library / regulatory-reference
Sri Lanka: National Medicines Regulatory Authority (NMRA)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The National Medicines Regulatory Authority, known as the NMRA, is Sri Lanka's regulator for medicines, medical devices and cosmetics. It was established under the National Medicines Regulatory Authority Act of 2015, replacing the earlier drugs and devices regulatory body, and operates under the Ministry of Health.
Sri Lanka has a mixed market of imports and a modest domestic industry, so the authority's registration and quality decisions determine most of what is prescribed in the country.
How products enter the market
Medicines require registration after evaluation of quality, safety and efficacy, and the authority licenses manufacturers, importers and wholesalers. Samples are tested through national quality-control laboratories, and advertising of medicines is restricted by law.
Post-market work includes pharmacovigilance reporting, market surveillance and recall powers.
Regional and international role
The authority participates in regional regulatory cooperation in South Asia and draws on international reference standards for parts of its evaluation.
Its legislative model, which consolidated medicines, devices and cosmetics under one authority, is frequently cited in regional discussions of regulatory modernization.
Using this profile
The authority publishes notices, guidelines and registration information in English, Sinhala and Tamil through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: the NMRA illustrates the consolidated small-state regulator: one authority covering medicines, devices and cosmetics, with statutory advertising controls.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.